PLoS One by Wu, Chao et al.
Avian Influenza A(H7N9) Virus Screening in Patients with
Fever and Flu-Like Symptoms in a Tertiary Hospital in an
Area with Confirmed Cases
Chao Wu1, Rui Huang2, Jianjun Chen3, Qin Gu4, Bin Zhu5, Jun Wang6, Kui Zhang7, Quanjiao Chen3,
Chaochao Xiong3, Yong Liu7,9, Jiequan Li8, Yi-Hua Zhou1,7,9, Yitao Ding9*
1 Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China, 2 Department of Infectious Diseases,
Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China, 3 Center for
Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, China, 4 Department of Intensive Care Units, Nanjing Drum
Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China, 5 Department of Radiology, Nanjing Drum Tower Hospital, Nanjing University Medical School,
Nanjing, Jiangsu, China, 6 Department of Emergency Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China, 7 Department of
Laboratory Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China, 8 Nanjing Municipal Center for Disease Control, Nanjing,
Jiangsu, China, 9 Jiangsu Key Laboratory for Molecular Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China
Abstract
Novel avian influenza A(H7N9) virus was isolated in fatal patients in Yangtze River Delta of China in March 2013. We aimed
to screen the virus in febrile patients in a tertiary hospital in an area with confirmed cases. Throat-swab specimens collected
from consecutive patients with fever ($38uC) and flu-like symptoms from April 15 to April 25, 2013 were subjected to detect
novel avian influenza A(H7N9) virus with real-time PCR. The clinical outcomes in the patients and close contacts were
followed up. Of total 200 patients screened, one (0.5%) was positive for avian influenza A(H7N9) virus and 199 others were
negative. The infected patient experienced respiratory failure and had diffuse infiltrates in the right lower lobe in chest CT
images. He received symptomatic and antibacterial treatments as well as oseltamivir. His condition was substantially
improved within three days after admission; avian influenza A(H7N9) virus was not detected after 5 days’ antiviral therapy.
The hemagglutinin inhibition test showed that the serum titers against avian influenza A(H7N9) virus increased from ,1:20
at the early phase to 1:80 at the convalescent phase. Follow-up of 23 close contacts showed that none of them developed
fever and other symptoms within two weeks. Our findings suggest that although the infection rate of avian influenza
A(H7N9) virus in patients with fever and flu-like symptoms is rare, the screening is valuable to rapidly define the infection,
which will be critical to improve the clinical outcomes.
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Introduction
During March 2013, a novel influenza virus of avian origin,
influenza A(H7N9), was isolated from three patients with fatal
severe respiratory disease in Shanghai and Anhui, both located in
the Yangtze River Delta Region, east part of China [1].
Subsequent reports show that the virus was detected in more
patients from the same areas, including Nanjing, the capital of
Jiangsu Province [2–4]. Up to August 11, 2013, a total of 135
patients, including 44 deaths, were confirmed to be infected with
the virus; most of them came from the Yangtze River Delta
including Nanjing city [5].
According to the diagnostic criteria, a suspected case of avian
influenza A(H7N9) is defined when a patient has fever, respiratory
symptoms such as sore throat or cough, toxemia symptoms such
as headache, malaise, or myalgia, and supportive epidemiologic
evidence such as contact with poultries and living at areas
where confirmed case was reported [6]. However, screening
for avian influenza A(H7N9) virus in febrile patients attending
the hospital in areas with confirmed cases is rarely reported
[7].
Nanjing Drum Tower Hospital is a 2,400-bed tertiary
medical center with 35 departments, including an emergency
department with the fever clinic and an independent
intensive care unit (ICU) with 51 beds and 6 isolation rooms.
During late March and early April 2013, five patients who
attended to our hospital were confirmed to have caught avian
influenza A(H7N9) [3]. This had us to assess the incidence of avian
influenza A(H7N9) virus in patients with fever flu-like symptoms,
who attended the fever clinic of our hospital, a major general
hospital in areas with confirmed cases of avian influenza
A(H7N9).
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Materials and Methods
Ethics statement
Written informed consent was obtained from all patients
involved in this study. The study was approved by the Ethics
Committee of Nanjing Drum Tower Hospital (EC20130411-1).
Samples and data collection
During the late March and the early April 2013, several patients
with high fever and server pneumonia were admitted to our
hospital. On April 2, two of them were confirmed to be infected
with avian influenza A(H7N9) virus by the Chinese Center for
Disease Control and Prevention in Beijing; one more patient was
confirmed the infection by the Jiangsu Provincial Center for
Disease Control and Prevention in Nanjing on April 4 [3,4]. Once
these three patients were diagnosed, we wanted to start screening
avian influenza A(H7N9) virus in patients with fever and flu-like
symptoms who attended to our hospital. However, we did not start
the screening until April 15 because of the short of detection
agents at that time. We stopped the screening after April 25
because rare cases had been confirmed to be infected with avian
influenza A(H7N9) virus within one week, the presumed
incubation period, before April 25. With the throat-swabs
specimens collectors, we collected the throat swab samples from
200 consecutive febrile ($38uC) patients with flu-like symptoms
when they first went to our hospital from April 15 to April 25.
Each swab was vigorously shaken in 0.5 mL of diethylpyr-
ocarbonate treated water and squeezed on the inside surface of
tube to release as much trapped virus as possible before the swab
was taken out. Each of the samples was added with 1.0 mL TRIzol
(Invitrogen, Life Technologies, USA), vortexed for at least 15 s,
and then stored at 270uC.
RNA extraction and detection of influenza A(H7N9) virus
The total RNA was extracted from samples in TRIzol
according to the manufacturer’s instructions. To increase the
recovery rate of RNA, we added 0.5 mL glycogen (20 mg/mL) in
the precipitation of RNA. The final pellet was dissolved in 10 mL
diethylpyrocarbonate treated water. Five microliters each was used
to detect H7 and N9 genes respectively with the fluorescence
reverse transcription (RT) PCR Detection kits (BioPerfectus
Technologies, Taizhou, Jiangsu Province, China) on ABI 7500
Real time PCR system (Applied Biosystems). The protocols and
primers were prepared in accordance with those provided the
WHO Collaborating Centre in Beijing [1].
Virus isolation
The virus isolation was performed essentially as described
previously [8]. Briefly, throat-swab specimens taken from patients
were maintained in viral transport medium on ice fewer than
24 hours, followed by filtration sterilization and inoculation into
the allantoic cavities of 10-day-old specific-pathogen-free (SPF)
embryonated eggs (Beijing MERIAL Ltd.). After incubation at
35uC for 48–72 h, the allantoic fluid of the inoculated eggs was
collected and identified by hemagglutination assay.
Hemagglutinin inhibition assay
The hemagglutinin inhibition (HAI) assay was performed with
0.5% chicken red blood cells as described elsewhere [9] with some
modifications. Briefly, the sera from patients were treated with
receptor-destroying enzyme (Denke-Seiken, Japan) and inactivated
at 56uC for 30 min, followed by incubation with chicken
erythrocytes to adsorb nonspecific agglutinins. Then the sera,
starting at a 20-fold dilution, were 2-fold serially diluted with PBS,
and added with 25 mL/well on a 96-well polystyrene microtiter
plate, followed by adding 25 mL of virus suspension containing 4
hemagglutinin units per well. After incubation of the plate at room
temperature for 1 hour, 50 mL of 0.5% (v/v) chicken red
blood cells was added to each well. After incubation at room
temperature for 30 minutes, the HAI titers were determined as the
reciprocal of the highest serum dilution that completely inhibited
hemagglutination.
Statistical analysis
Statistical analysis was performed using SPSS software version
13.0 (SPSS, Chicago, USA). We summarized the continuous
variables as means and standard deviation. For categorical




From April 15 to April 25, 2013, totally 5,009 patients attended
to the outpatient emergency department of our hospital. Of them,
337 with fever $38uC were required to attend the fever clinic of
our hospital. A total of 200 febrile patients, who also presented flu-
like symptoms, were recruited in this study to have their throat-
swab specimens tested for the presence of avian influenza
A(H7N9) virus with fluorescence RT-PCR. Their general
characteristics and results of routine blood tests are shown in
Table 1.
One (0.5%) of the 200 patients showed positive in the tests of
both avian influenza virus H7 and N9 in RT-PCR and 199 others
(99.5%) were negative. Additional throat-swab specimens from the
Table 1. General characteristics and routine blood test results
of the 200 febrile patients.














Leukocyte count, 6109/L 10.1864.14
,46109/L 5 (2.5)
.106109/L 93 (46.5)
Lymphocyte count, 6109/L 1.4361.01
Neutrophil, 6109/L 7.9363.91
Hemoglobin, g/L 140.10617.73
Platelet count, 6109/L 180.25646.37
*Values are no. patients (%) or mean 6 standard deviation.
doi:10.1371/journal.pone.0082613.t001
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patient with positive avian influenza A(H7N9) virus RNA, which
had been collected the next day, were retested with the same kit in
two other independent laboratories; both laboratories reported
positive. Thus the patient was diagnosed with the infection of
avian influenza A(H7N9) virus. All other patients were excluded
from the infection of the virus, and recovered after 1–3 weeks
treatment.
Illustration of the patient infected with avian influenza
A(H7N9) virus
The patient diagnosed with the infection of avian influenza
A(H7N9) virus was a 36-year-old man who lived in Xinyi city,
which is located in north part of Jiangsu Province, 310 km away
from Nanjing. He was a living poultry retailer and had transported
living poultry from Xinyi city to Hangzhou city, the capital of
Zhejiang Province, where sporadic avian influenza A(H7N9)
occurred from February to April, 2013 [2,4]. He had a known
exposure history to live chicken within a week before the onset. He
developed fever (38.4uC), non-productive cough, malaise, and
myalgia on April 18, and his condition was deteriorated with the
highest temperature 40.5uC and dyspnea on the subsequent days.
The patient was referred to our hospital on April 22, 2013.
On the physical examination in our hospital, the patient had
high fever (40.2uC), dyspnea and lip cyanosis. Blood tests revealed
Figure 1. Chest radiographs and computed tomographic (CT) scans in the patient with avian influenza A(H7N9). (A and B) Chest
radiographs taken 5 and 25 days respectively after the onset of symptoms. Diffuse infiltrates and consolidation may be observed in the right lower
lobe on day 5 (A) and the infiltrates are largely disappeared on day 25 (B). (C to F) Chest CT scans during the illness course and follow-up. The
scanning was performed on day 4 (C), 21 (D), 43 (E), and 75 (F) respectively after the onset of symptoms.
doi:10.1371/journal.pone.0082613.g001
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that leukocytes were 3.36109/L with neutrophils of 2.66109/L,
lymphocytes of 0.56109/L, platelet of 936109/L, and red blood
cells 4.3861012/L, and the liver and kidney functions were
generally normal. The sputum cultures for bacteria in the first
three days were all negative. Arterial blood gas analysis presented
the results of pH 7.441, PO2 64 mmHg, PCO2 30.5 mmHg, and
SaO2 93%, under nose tubular oxygen supplement (5 L/min).
Chest x-ray and computed tomographic (CT) scanning revealed
consolidation and diffuse infiltrates in the right lower lobe and
patchy infiltrates in the left lower lobe (Figure 1A and 1C). He was
diagnosed with severe pneumonia (suspected H7N9 influenza) and
respiratory failure. He was admitted to the Respiratory Depart-
ment, and given the oseltamivir (150 mg, twice daily) and
antibiotics as well as other symptomatic treatment. Meanwhile,
throat-swab samples were collected for detecting avian influenza
A(H7N9) virus, which turned out to be positive on the test of April
23. On the next day, throat-swab samples were collected again for
detecting avian influenza A(H7N9) virus; the viral RNA was
positive in the two independent laboratories reported on April 24.
Once the diagnosis was established on April 24, the patient was
quarantined in the isolation room to prevent the potential
transmission and treated with the combination therapy against
influenza A, including oseltamivir and piperacillin/tazobactam
(Tazocin). The main clinical features, laboratory findings, and
treatment during the disease course are presented in Figure 2. The
patient received continuous nasal oxygen supplementation (2–
5 L/min) in the period of April 23–April 25 and intermittent nasal
oxygen supplementation (2 L/min) during April 26 and 27; he
never used mask oxygen inhalation or mechanical ventilation. The
patient’s condition was substantially improved within three days
after admission; the dyspnea disappeared and hypoxemia was
corrected. The isolation of the virus from the throat-swab sample
collected on April 25 was failed even after the sample was
propagated in the allantoic sac and amniotic cavity of embryo-
nated chicken eggs. Avian influenza A(H7N9) virus RNA in the
throat-swab samples was still positive on April 26 but became
undetectable on April 28 and remained negative thereafter, while
the viral RNA was undetectable in the serum samples collected on
the April 23, 26, and 28 respectively. The chest CT-scanning on
May 9 showed that the patchy infiltrates in the left lower lobe
disappeared and the diffuse infiltrates in the right lower lobe
significantly improved (Figure 1D). In agreement with this, no
consolidation was observed on the chest x-ray on May 13
(Figure 1B). On May 15, the patient was discharged after he had a
good recovery. The follow-up on May 31 showed that the physical
examinations were generally well and hematological and bio-
chemical investigations did not reveal abnormal results, but his
chest CT-scanning still had some abnormal in the right lower lobe
(Figure 1E). A further follow-up conducted on July 2 revealed no
abnormal findings in physical examinations, blood tests and chest
CT-scanning (Figure 1F).
The hemagglutinin inhibition test showed that the serum at the
early phase of the illness, on day 6 after the onset, had the titers
lower than 1:20 against avian influenza A H7N9, H5N1, and
2009H1N1, respectively, but had a titer of 1:80 against seasonal
influenza A H1N1. However, the serum of convalescent phase, on
day 44 after the onset, had titers of 1:80 against avian influenza
A(H7N9) virus (Table 2).
Contact tracing
The patient had not been quarantined until his diagnosis was
established on April 24, 2013. Some persons closely contacted the
patient without strict preventive measures. These included his
parents, his wife and two children, and 18 physicians and nurses.
We followed these persons to investigate whether avian influenza
A(H7N9) virus was transmitted from human to human. None of
the 23 close contacts developed the fever and flu-like symptoms
within 14 days after contact.
Figure 2. Course of the patient infected with novel avian influenza A(H7N9) virus. HAI, titers of hemagglutinin inhibition against the novel
avian influenza A(H7N9) virus.
doi:10.1371/journal.pone.0082613.g002
Table 2. Hemagglutinin inhibition titers of the sera at
different phases of the illness.
Serum
Virus isolate Acute phase Convalescent phase
A/Shanghai/2/2013 (H7N9) ,20 80
A/Anhui/1/2013 (H7N9) ,20 80
A/Chicken/Hunan/246/2012 (H5N1) ,20 ,20
A/California/07/2009 (H1N1) ,20 20
A/New Caledonia/20/99 (H1N1) 80 80
doi:10.1371/journal.pone.0082613.t002
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Discussion
In the present study, we investigated the novel avian influenza
A(H7N9) virus in the patients with fever and flu-like symptoms in
an area with confirmed cases during the onset season. Of the 200
patients investigated, one (0.5%) was defined with infection of the
virus, indicating that, even in areas with the confirmed cases
during the onset season, the infection rate of avian influenza
A(H7N9) virus in the flu-like patients is low. However, the
incidence is higher than that (0.03%) in 20,739 patients with
influenza-like illness from 10 provinces with confirmed human
cases [7]. The results that none of the 23 close contacts of the
patient with influenza A(H7N9) developed flu-like symptoms
suggest that the virus is not easily to transmit from human to
human, which is in agreement with the other reports [10–12].
In this investigation, no patient with fever and flu-like symptoms
who attended to the Emergency Department of our hospital
during the screening period refused to participate, indicating that
no patient infected with avian influenza A(H7N9) virus was
neglected. Furthermore, the screening method, developed accord-
ing to the protocols of the WHO Collaborating Centre in Beijing
[1], is highly sensitive and effective in detecting the viral RNA in
the throat-swab specimen [13]. Thus, it is less likely to
underestimate the infection rate of avian influenza A(H7N9) virus
in the patients with flu-like symptoms. Although the definitive
etiological diagnosis were not clear, the benign outcomes of 199
other patients also suggested that they were not infected with avian
influenza A(H7N9) virus. On the other hand, it is also impossible
that the diagnosis of avian influenza A(H7N9) virus infection is a
result of false positive, although the viral culture of throat-swab
specimen from this patient was negative. The reasons supporting
the diagnosis include: (1) the RNA of avian influenza A(H7N9)
virus was detected in three independent laboratories; (2) the
clinical features and disease course are in agreement with those of
the patients with avian influenza A(H7N9); and (3) the most
important, the hemagglutinin inhibition test against two isolates of
the novel avian influenza A(H7N9) virus (Table 2) had the titers
increased by .4-fold from the early phase to the convalescent
phase.
Since avian influenza A(H7N9) virus causes fatal disease in
human, one of main concerns on this disease is the issue of
whether the virus is prone to human-to-human transmission. In
the present study, we traced the close contacts who had not taken
the precautionary measures, and none of them developed flu-like
symptoms. The results imply that the human-to-human transmis-
sion of the avian influenza A(H7N9) virus appears to be rare,
although it is reported that the virus can bind to human-type a2,6-
linked sialic acid receptors, and infect epithelial cells derived from
the human lower respiratory tract and type II pneumonocytes
derived from the human alveoli [14]. Our data are consistent with
the results of other studies [15,16].
It is interesting to note that the patient infected with avian
influenza A(H7N9) virus found in this screening had experienced
the disease not as severe as most of the other reported patients [4].
In accordance with the benign course of the disease in this patient,
the duration (8 days after the onset) of viral shedding in the throat
swab specimens was also relatively short, compared with that
reported elsewhere [13]. The relatively good clinical course in this
patient may be attributed to several reasons. The first may be that
the patient received the early treatment after the onset of the
illness; this is attributed to the rapid response to the outbreaks of
avian influenza A(H7N9) and the development and attribution of
detection reagents. The second may be that the patient is much
younger (36 years old) compared to those in a report with 111
patients (61 years old, median). Ip et al reported that 5 patients at a
mean age of 13 years (range 2–26 years) had mild to moderate
infection of avian influenza A(H7N9) virus, and three of them were
even not hospitalized [16], suggesting that young persons may
have benign prognosis than old ones. A more relevant example is
that a 15-year-old boy appeared to have caught moderate avian
influenza A(H7N9) and recovered after one week hospitalization;
he was respectively diagnosed nearly after two months [17]. On
the other hand, elderly people may have increased risk for H7N9
virus infection and have worse outcomes [10,18].
In summary, although the infection rate of avian influenza
A(H7N9) virus in an area with confirmed cases during the disease
season is rare, the screening in patients with fever and flu-like
symptoms is valuable to rapidly diagnose the patients in areas with
confirmed cases during certain period of time, which will be
critical to improve the disease outcomes and prevent the potential
spread of avian influenza A(H7N9) virus.
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